Dear zeeuw,
I guess I'm not getting my point across clearly enough. BP is not as interested in issues of Atryns acceptability, stability, safety, or reliability as it is in the question will adopting a transgenic platform delay or lengthen the time it takes to get a product through the regulators. The time issue at present is more important than all of GTCB's advantages. BP has not lined up as anticipated to ask GTCB to manufacture drugs for them because GTCB's platform takes longer startup time than cell culture.
The lack of interest by BP has undoubtably decreased anticipated revinue streams and has put a damper on the PPS.
IMHO this in no way effects the company in a long range way. There science is great their future as good as it gets. They will be delayed somewhat but unless real bad luck intervenes they are well on their way to developing revinue streams and they have such an advantage in plasma protiens in the long run they wont need BP.
As far as I know LFB is blocked from owning more shares.
Market Data 
Markets 
AI
